2) I am Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert and now we are covering @myESMO #ESMOImmuno22 updates/review on “Biomarker Targeted Therapies” in #LCSM! pic.twitter.com/sJb9PPWYFH
— @onc_ce (@onc_ce) December 15, 2022
2) I am Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert and now we are covering @myESMO #ESMOImmuno22 updates/review on “Biomarker Targeted Therapies” in #LCSM! pic.twitter.com/sJb9PPWYFH
— @onc_ce (@onc_ce) December 15, 2022
6) At @myESMO #ESMOImmuno22 we saw data on #adagrasib (#KRASG12C inhibitor) with #immunotherapy, with some studies on newer #IO combinations! In this 🧵 we will discuss #biomarker based #LCSM approaches with some updates! @HemOncFellows @Oncbrothers pic.twitter.com/WOzcVhqAyF
— @onc_ce (@onc_ce) December 15, 2022
8) #EGFR really the first targeted for #LCSM
— @onc_ce (@onc_ce) December 15, 2022
✅Not all EGFR mutations are the same!
✅Osimertinib=tx for most activating #EGFR mutations
based on #ADAURA trial adjuvantly now ➡️Osimertinib 80 mg once daily for 3 years
🔓https://t.co/r9bNTYFutE pic.twitter.com/2INZ7PDNun
10) #KRASG12 now druggable in 2L! Really exciting year for #KRASG12C #LCSM with 📊📈presented @AACR @ASCO#ASCO22 @IASLC#WCLC22 and now @myESMO #ESMO22 #ESMOImmuno22! Here’s #Onc1Slider on #KRASG12C #LCSM
— @onc_ce (@onc_ce) December 15, 2022
To 🔄🧠! pic.twitter.com/zO8F4xT22K
12) Now @myESMO #ESMOImmuno22 Dr. Janne presented (KRYSTAL1/7) data on #adagrasib + #pembrolizumab 1L
— @onc_ce (@onc_ce) December 15, 2022
🛑G3>= TRAEs: 44%, 0 grade 5‼️
➡️ORR: 49% @KRASKickers #LCSM pic.twitter.com/6Pll4Psf91
14) Newer emerging #biomarkers with current 2L approvals are:
— @onc_ce (@onc_ce) December 15, 2022
➡️ EGFR ex20 ins: Capmatinib, Tepotinib: 🔓https://t.co/jzV8mZeNuK
➡️ ERBB2 mutations: TDx-d 🔓https://t.co/m4bP3IGFLX pic.twitter.com/qwRInfqCAy
16) It’s C!
— @onc_ce (@onc_ce) December 15, 2022
Biomarkers for the #antibody-drug conjugates #ADCs are under investigation but keen interest in:
➡️ HER2, HER3, TROP2, MET, CEACAM5 for #LCSM #NSCLC
➡️ DLL3 for #SCLChttps://t.co/YDODIqvSNz@Alfdoc2 pic.twitter.com/r9sVyaS7hm
18) As we look forward, more 🎯💊 therapies we need novel targets, #CEACAM5 #overexpressed in #LCSM
— @onc_ce (@onc_ce) December 15, 2022
➡️ 38% AdenoCA, 20% SqCC stain for #CEACAM5 @Oncoalert 🔓https://t.co/mE0GnGgv3Z pic.twitter.com/aLS9R2HyuR
20) Sneak peek into #ADCs also entering the #metastatic #oncogene driven #LCSM #NSCLC presented at #ASCO22 @ASCO
— @onc_ce (@onc_ce) December 15, 2022
➡️ Telisotuzumab Vedotin (MET ADC) with #osimertinib
➡️ Dato-Dxd
➡️ Patritumab Dxd #EGFRm #LCSM @EGFRResisters pic.twitter.com/3VCo24uqya
22) Now go to https://t.co/ZUZZSjyvFC to claim your 🆓CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. FOLLOW US here @onc_ce for more #accredited #tweetorials by expert authors!
— @onc_ce (@onc_ce) December 15, 2022